Platforms · Access · Governance
Organoid Grid
A publication about who builds the platforms that run computation on living tissue, who can actually get access to them, and who decides what is permissible. We read vendor claims against published specifications, and we take the governance questions as seriously as the engineering.
Latest analysis
July 29, 2026 Long-term epithelioid cultures and living-tissue governanceA bioRxiv preprint presents human epithelioids, self-sustaining 3D cultures from eight adult tissues held for two to eight months while preserving donor-specific mutations. For platform governance the decisive variable is temporal persistence, the property that most sharpens moral-status and biobanking questions for living, and especially neural, tissue.
July 29, 2026
A terminated micro-organosphere pilot and platform access
A single-site pilot of patient-derived micro-organosphere drug screening in advanced breast cancer was terminated at the sponsor's request with 7 of 15 patients and no posted results. The record is a lesson in how vendor platform capability and clinical access come apart, and how the consent chain becomes the real governance layer.
July 28, 2026
A psychiatric classifier built on cerebral-organoid network dynamics
An NIH R01 proposes a standardized multi-electrode-array and machine-learning platform to classify schizophrenia and bipolar disorder from cerebral-organoid activity. We read what it changes for platform access, vendor capability, and the governance of computing on living neural tissue.
July 28, 2026
Predicting organoid quality, and who gets to define it
A new multi-PI NIH R01 wants early metrics that forecast which stem-cell lines will differentiate into usable brain organoids. We read what a predictive quality-control gate changes for platform access, vendor power, and any governance built on organoid readouts.
July 27, 2026
The benchmark that could gate an industry
An NIGMS grant proposes AI fidelity scorecards that rank how human an organoid model is. If such a metric were widely adopted, whoever owned it would hold a governance chokepoint, and applied to neural tissue it could optimize blindly toward the moral status line.
July 27, 2026
The event camera that never needed a neuron
A neuromorphic silicon sensor tracks and sorts microparticles by color and size at sub-millisecond speed with no learning step. For a field selling computation on living neural tissue, the interesting part is what the word neuromorphic is doing.
July 26, 2026
Organ-chips become systems, and access becomes integration
A modular respiratory-vascular organ-on-chip recapitulates COPD endothelial dysfunction from epithelial oxidative stress. The capability that matters for platform access is systems integration, not any single chip.
Start here
Standing explainers that do not go stale. Read the comparison first if this field is new to you.
The comparison
Biocomputing platforms, compared honestly
A dated, vendor-neutral comparison of the platforms you can actually access, the metrics that matter, and the caveats vendors leave out.
Survey
The biological-compute platform landscape, compared
Every platform you can currently reach, on one page, with the access model and the numbers that matter.
Vendor
Cortical Labs
The CL1 system: what it is, what it costs to run, and what the published results support.
Vendor
FinalSpark
The Neuroplatform remote-access model, and what running experiments over the internet changes.
Sections
Section
Platforms
The commercial and academic platforms offering access to living neural tissue, what each one actually provides, and how to read a spec sheet that was written to sell.
Section
Ethics and governance
Moral status, oversight, consent, and the policy vacuum the field is operating in.
Section
Analysis
Daily readings of new research, each asking what the work changes for this field.
How we work
We compare platforms on published specifications and peer-reviewed results, never on marketing copy, and we date every comparison because this market moves. Where a vendor funds or authors the work we are citing, we say so. On the ethics side we distinguish what is currently regulated from what is merely customary, and we do not present a philosophical position as a settled finding. The full method, including how pieces are selected and produced, is on the about page.